Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

A new injectable weight loss treatment from the maker of Ozempic and Wegovy delivered 23% weight loss in trials, according to findings published in the New England journal and medicine. Dr ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

Eli Lilly faced a reality check as HSBC downgraded its stock twice, citing inflated optimism about its weight-loss drugs. Wall Street is underestimating the risk to Lilly from its main weight-loss ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Eli Lilly, the maker of Ozempic, has developed a weight loss pill that could work as well. The new weight loss pill, orforglipron, is a once-daily oral GLP-1 receptor agonist that is designed to ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why LLY stock is a buy.

Orforglipron, an experimental treatment Eli Lilly is developing for diabetes and weight loss, hit high marks in the first of several pivotal trials.

Eli Lilly invests $27B in U.S. manufacturing for a weight-loss pill as demand grows.

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, stab-free way to treat diabetes and obesity.